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Summary: X-linked severe combined immunodeficiency disease
(SCID) is caused by mutations in the interleukin (IL)-2 receptor γ
(IL2RG) gene and patients usually present with a T−B+NK− SCID
phenotype. Nevertheless, a minority of these patients present with a
T−B+NK+ phenotype, similar to the IL-7R-deficient patients. We
report a patient with a novel missense p.Glu297Gly mutation in the
IL2RG gene presenting with a leaky TlowB+NK+ SCID with
delayed onset, moderate susceptibility to infections, and nodular
regenerative hyperplasia. He presents with preserved STAT5 tyro-
sine phosphorylation in response to IL-15 stimulation but not in
response to IL-2 and IL-7, resulting in the NK+ phenotype.
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S evere combined immunodeficiency diseases (SCIDs) area group of genetic disorders that result in the absence or
dysfunction of T and B lymphocytes. Without adequate
diagnosis and treatment, patients usually succumb to
infection during the first 2 years of life.1
Classically considered as having an incidence of 1 in
75,000 to 100,000 births, its real incidence is becoming
clearer with the introduction of newborn screening and is
estimated to be around 1:58,000 births.2
X-linked SCID is the most common form of SCID and
is caused by mutations in the interleukin (IL)-2 receptor γ
(IL2RG) gene (OMIM 208380), which encodes the common
cytokine receptor γ chain (γc). This protein is a subunit of
several receptors that recognize cytokines IL-2, IL-4, IL-7,
IL-9, IL-15, and IL-21. It is essential for the signal trans-
duction, by interaction with Janus Kinase 3 (JAK3) and
subsequent phosphorylation and activation of the signal
transducer and activator of transcription (STAT) proteins
that regulate the induction of gene transcription.3,4
The pivotal role of signaling of each of these cytokines
has been clearly showed: IL2 signaling is crucial for the
maintenance of peripheral tolerance, IL-4 and IL-21 sig-
naling defects are responsible for the intrinsic B-cell defi-
ciency, IL-7 signaling defect causes abnormal/absent T-cell
development, and abnormal signaling of IL-15 leads to the
natural killer (NK) deficiency. The combination of these
cytokine signaling defects explain the T−B+NK− SCID
phenotype observed in the majority of patients harboring
mutations in the IL2RG gene.3–5
There are few reports of leaky-X-SCID patients, pre-
senting with a less severe phenotype, prolonged survival,
and atypical manifestations (including 2 adult patients pre-
viously diagnosed as having common variable immunode-
ficiency) (Table SI, Supplemental Digital Content 1, http://
links.lww.com/JPHO/A255).3,6–10
These leaky-XSCIDs can be caused by hypomorphic
regulatory mutations or reversion mutations in the IL2RG
gene.7–10
Interestingly, a minority of X-SCID patients present
with a T−B+NK+ phenotype, similar to the IL-7R-deficient
patients.11
This is in accordance with the preserved signaling by
the IL-15R, as it has been shown before that signal trans-
duction by the IL-7R is crutial for T-cell development but is
dispensable for NK cell development, whereas adequate
signaling via the IL-15R is essential for NK cell but not for
T-cell development.3,4,12
Here, we report a patient with a novel missense p.
Glu297Gly mutation in the IL2RG gene presenting with a
leaky TlowB+NK+ SCID with delayed onset of disease,
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moderate susceptibility to infections, inflammatory bowel
disease, and nodular regenerative hyperplasia (NRH). He
had no signs of a reversion mutation and had reduced but
not absent expression of γc leading to a preserved STAT5
tyrosine phosphorylation (STAT5-pTyr) in response to IL-




For the evaluation of lymphocyte subsets, peripheral
blood was analyzed by flow cytometry in a 4-color BD
FACS Calibur (BD, San Jose, CA), using the BD IMK kit
with Trucount tubes (BD Biosciences) according to the
manufacturer’s instructions. An additional panel of mono-
clonal antibodies (including CD45RA, CD45RO, CD62L,
and HLA-DR) was also performed for further character-
ization of T-cell differentiation, using a lyse-wash protocol.
Finally, the IOTest Beta Mark kit (Immunotech SAS, a
Beckman Coulter Company, Marseille, France) was also
used for the characterization of the TCR Vβ repertoire.
For the liver biopsy, the sample was mechanically
disaggregated in a Medicon chamber (BD Biosciences),
recovered, and resuspended in phosphate buffered saline.
The cell suspension was incubated with the BD IMK kit
(BD Biosciences) in regular flow cytometry tubes, using a
lyse-wash protocol.
Flow cytometry data analysis was performed using
Multiset and CellQuest Pro software (BD Biosciences).
Proliferation Assays
Proliferative capacity was performed with a thymidine
incorporation assay. In brief, peripheral blood mononuclear
cells were incubated with mitogens: PHA (6.25 μg/mL) and
PMA+ionomycin (10−7M+10−5M) for 3 to 4 days, and with
antigens: PPD (5 μg/mL), Candida albicans antigen (50 μg/
mL), and tetanus toxoid (230 ng/mL) for 7 to 8 days, at 37°C,
in a 5% CO2 atmosphere. The cells were labeled with tritiated
thymidine (3H-thymidine) (Perkin Elmer, Boston, MA) in the
last 18 hours of incubation,. Cells were then harvested and
transferred to a Filtermat A filter (Perkin Elmer), and a
Meltilex cintillation sheet (Perkin Elmer) was applied after the
Filtermat was dried. The radioactivity in the DNA recovered
from the cells was read in a MicroBeta counter (Perkin
Elmer). Results were presented as stimulation indexes,
obtained from the ratios of counts per minute from stimulated
and unstimulated cells (incubated in parallel).
Antibody Response Evaluation
Immunoglobulins were quantified in serum. Immuno-
nephelometry (BN II, Siemens Healthcare, Germany) was
used to quantify IgG, IgA, and IgM. As for specific
responses, antibodies for diphtheria, tetanus (Binding site,
UK), and Pertussis (EuroImmune, Germany) were eval-
uated by enzyme-linked imumnosorbent assay.
Exome Sequencing and Bioinformatics Analysis
We isolated DNA samples from blood or peripheral
blood mononuclear cells. Library preparation, exome cap-
ture, and sequencing have been carried out according to the
manufacturers’ instructions. For exome target enrichment
Agilent SureSelect 50Mb kit was used. Sequencing was
done using Illumina HiSeq. 2000 with 94 bp paired-end
reads. FASTQ files were aligned to the hg19 reference
sequence using Novoalign version 2.07.19, including hard
and soft clipping, quality calibration, and adapter trimming.
A total of 82.8 million reads were generated and analyzed.
Duplicate reads were excluded using the PICARD tool
MarkDuplicates. Calling was performed using SAMtools
version 0.18 and single sample calling. The resulting calls
were annotated with the software ANNOVAR. Candidate
variants were filtered based on function: loss-of-function,
nonsynonymous, or potential splicing altering variants
(defined as being with 5 bp of the actual splice site) and
frequency.
Histopathologic Examination
A wedge liver biopsy was performed, 2 cm in length,
stained using hematoxylin eosin, Masson trichrome, Red
sirius, Perls, reticulin, and CK7 immunohistochemistry.
IL2RG Expression and STAT5 Phosphorylation
Assay in Patient Blood
The 3 μL of anti–human IL2RG (BD Biosciences) or
matched isotype control (BD Biosciences) was added to 100
μL of blood, incubated for 10 minutes at room temperature.
Red blood cells were lysed with FACs Lsye (BD Biosciences)
for 10 minutes and then washed with Cell Wash (BD Bio-
sciences) before being fixed (FACsFix, BD Bioscience). In
total, 10,000 lymphocytes were acquired (FACs Calibur, BD
Biosciences) and analyzed (CellQuest Pro, BD Biosciences)
For STAT5 phosphorylation assay, cells were left unstimu-
lated or 1×104 IU/mL IL-2 (Chiron) or 50 ng/mL IL-7 or IL-
15 (R&D systems) were added to 100 μL of whole blood and
placed at 37°C for 10 minutes. Two milliliters of prewarmed
FACs Lyse/Fix (BD Biosciences) were then added to the
blood, mixed, and placed at 37°C for a 10 minutes. The cells
were pelletted and washed once with (Invitrogen) containing
1% fetal calf serum (STAT wash). The cells were resupended
in cold Perm Buffer III (BD Biosciences) and placed at 4°C
for 30 minutes. The cells were then washed once with STAT
wash before 5 μL of antibodies (STAT5-ptyr and CD4
PerCP [BD Biosciences]) were added, and the cells were
incubated at room temperature for 30 minutes in the dark,
washed with STAT wash, and fixed (FACsFix, BD Bio-
sciences). In total, 10,000 lymphocyte events were acquired
(FACs Calibur, BD Biosciences) and analyzed using Cell-
Quest Pro software (BD Biosciences).
RESULTS—CASE REPORT
A 3-year-old boy was admitted for pneumococcal pneumonia
with empyema, requiring intensive care. His parents were not con-
sanguineous and he had 2 maternal uncles that died due to over-
whelming infection before the age of 12 months. He also had
chronic diarrhea since the age of 2 years. His immunologic workup
revealed moderate CD3+ lymphopenia (538 cells/μL), very reduced
naive CD4+ counts but normal numbers of B and NK cells. The
Vbeta repertoire was diverse and polyclonal and there was no
maternal engraftment. His proliferative responses were maintained
after stimulation with mitogens (anti-CD3, PHA, and PMA), but
responses to recall antigens (PPD, candida, and TT) were severely
depressed. He had normal IgG, borderline IgA, and borderline-low
IgM. He mounted a moderate response to diphteria, but not to
tetanus, 4 weeks after vaccination with DTPa (diphteria, tetanus,
acellular pertussis), but 3 months after vaccination the titere became
nonprotective (Table 1).
He was diagnosed with TlowB+NK+ leaky-SCID but his
parents refused hematopoietic stem-cell transplantation (HSCT).
Subcutaneous immunoglobulin replacement, as well as cotrimox-
azole prophylaxis were promptly initiated. From the age of 3 to
8 years, he had Cryptosporidium parvum infection for which he
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TABLE 1. Immunologic Assessment of the Patient
T-Cell Function 3 y Old 4 y Old 5 y Old 6 y Old 7 y Old 9 y Old
Absolute lymphocyte count (×109/L) 1120 1043 1175 1270 1400 375
CD3+ (cells/μL) (n [%]) 538 (44) 684 (54) 641 (54) 720 (55) 869 (66) 287 (79)
CD4+ (cells/μL) (n [%]) 257 (21) 313 (24) 262 (23) 279 (21) 296 (23) 139 (39)
CD4+CD45RA+ (%) 30 28 20 19 26 9
CD8+ (cells/μL) (n [%]) 171 (14) 230 (1) 230 (20) 264 (20) 360 (27) 105 (30)
CD8+CD45RA+ (%) 68 70 50 58 59 43
CD16+/56+ (cells/μL) (n [%]) 171 (14) 147 (12) 334 (27) 337 (26) 318 (24) 48 (13)
Proliferative responses to PHA (CPM ×103)
(stimulation Index; normal > 50)
25,621± 1762 (133) 12,083± 2982 (182) ND ND 17.366± 1.045 (10.7) 4.195± 1.138 (3.8)
Proliferative responses to PMA+I (CPM ×103)
(stimulation Index, normal > 50)
21,665± 2320 (75) 35,372± 3071 (531) ND ND 6.677± 0.864 (12.9) 0.773± 0.432 (1.9)
Proliferative responses to anti-CD3 (CPM ×103)
(stimulation Index, normal > 50)
ND 9743± 610 (146) ND ND ND 1.235± 1.233 (2.2)
Proliferative responses to PPD+I (CPM ×103)
(stimulation Index, normal > 10)
177± 40 (1) 599± 340 (7) 323± 220 (3.5) ND 0.325± 0.048 (0.6) 2.716± 0.828 (1.7)
Proliferative responses to Candida albicans
(CPM ×103) (stimulation Index, normal > 10)
149± 26 (0.8) 98±28 (1.2) ND ND 0.249± 0.088 (0.4) 1.368± 0.505 (0.9)
Proliferative responses to TT (CPM ×103)
(stimulation Index, normal > 10)
ND 0.324±0.209 (0.6) ND ND 0.272± 0.109 (0.5) 2.713± 1.056 (1.7)
B-Cell Function 3 y Old 3.5 y Old 4 y Old 5 y Old 6 y Old 7 y Old 9 y Old
CD19+ (cells/μL) (n [%]) 403 (33) 408 (32) 212 (16) 200 (16) 212 (16) 108 (8) 17 (5)
CD19+CD27−IgD+IgM+ (%) ND ND 95 ND ND ND 89
CD19+CD27+ (%) 2 ND 3 ND ND ND 10
CD19+CD27+IgD− (switch) (%) 1 ND 1 ND ND ND 2.5
CD19+CD38+IgM high (transitional) ND ND 16 ND ND ND 22
IgG (g/L) 10.2 12.2 12.4 10.6 11.8 12.6 11.5
IgM (g/L) 0.46 0.70 ND 0.6 0.4 0.3 0.3
IgA (g/L) 0.92 1.0 ND 1.1 0.9 1.2 1.2
Antidiphteria 0.27 1.25 0.05 ND ND ND ND
Antitetanus 0.12 0.05 0.05 ND ND ND ND
↑Diphteria, tetanus, acellular pertussis vaccination.
↑Subcutaneous immunoglobulin substitution.



























































received paromomycin and nitazoxanide; Epstein-Barr Virus vir-
emia complicated by severe colitis and toxic megacolon; mild var-
icela and 2 episodes of zoster; at the age of 8, he had Microsporum
canis tinea corporis for which he received a 3-week regimen of
itraconazole and then received prophylatic itraconazole. At the age
of 9 years, he presented splenomegaly which led to the diagnosis of
severe portal hypertension caused by NRH. The liver biopsy
revealed that the normal architecture was mildly distorted by
widespread atrophy and numerous monoacinar regenerative nod-
ules without fibrosis (Fig. 1). There was a lymphocytic infiltrate,
composed of 60% of CD3+, of which 25% CD4+, 50% CD8+, and
25% CD4CD8−, and 40% of NK cells. No pathogens were
identified.
Simultaneously, he presented with intestinal bleeding and the
biopsies were suggestive of inflammatory bowel disease. He had
positive norovirus PCR in the stools and colonic biopsies. He
received oral IvIG, as well as low-dose steroids and infliximab. He
has recently received HSCT from a matched unrelated donor fol-
lowing a reduced-intensity conditioning protocol.
No mutation was found in the targeted analysis of the IL7Rα
and RAG1/2 genes of the patient. However, whole exome
sequencing identified a novel hemyzigous missense p.Glu297Gly
mutation in the IL2RG gene (ENST00000374202: exon 7: c.890
A>G) (Fig. 2). Sanger sequencing confirmed the finding and
FIGURE 1. Hepatic histology reticulin silver impregnation high-
lighting subtle distortion of liver architecture with diffuse nodules
of hyperplastic hepatocytes and regions of internodular hep-
atocyte atrophy, at low power (original magnification, ×25).
FIGURE 2. p.Glu297Gly mutation in the IL2RG gene.
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showed that his mother was heterozygous for the same mutation,
whereas his father had a wild-type allele. The p.Glu297Gly muta-
tion was never detected previously, for example, it is absent from
single nucleotide polymorphism database and > 120,000 subjects in
the gnomAD database. Bioinformatics analysis predicted that the
mutation affected a highly conserved amino-acid residue. The p.
Glu297Gly mutation was predicted to be probably pathogenic
(SIFT—deleterious; PolyPhen2—possibly damaging; Mutation
Taster—neutral). His mother was heterozygous for the same
mutation.
He did not have signs of reversion mutation as assessed by
next-generation sequencing in DNA isolated from whole blood.
FACS analysis showed significantly reduced γc expression on
patient’s cells (Fig. 3A). To understand his clinical and immuno-
logic phenotype, we studied STAT5 phosphorylation in lympho-
cytes after stimulation with various cytokines.
We found reduced STAT5-pTyr in the patient after stim-
ulation with IL-2 and IL-7. However, he had very high basal level of
STAT5-pTyr and a largely preserved level of STAT5-pTyr after IL-
15 stimulation (Figs. 3B, C).
DISCUSSION
The hypomorphic presentation of the disease, as well as
the parental refusal of HSCT at the moment of the diag-
nosis, allowed longer than usual observation of the natural
course of this disease caused by a novel mutation in the
IL2RG gene. The patient progressively had more severe and
frequent infections that were mostly caused by viruses. In
parallel with this, his immune function worsened over time,
with progessive decline of the number of T cells, as well as
loss of the proliferative responses to mitogens which were
preserved in the first years after the diagnosis.
To our knowledge, this is the first X-SCID patient that
presented NRH, a rare liver condition characterized by the
presence of widespread small regenerative nodules in the
absence of fibrosis. It is thought to result from intrahepatic
vasculopathy leading to alterations in microvascular perfu-
sion, hepatocyte injury, and regeneration which contribute
to the formation of nodules that compress the portal and
central veins and thus potentially causing portal
hypertension.13 NRH has been well described in common
variable immunodeficiency patients and is thought to result
from the invasion of the hepatic parenchyma by CD8+ cells,
leading to hepatocyte loss, followed by regeneration which
causes vascular abnormalities and portal hypertension.14 It
is plausible that in our patient the imune dysregulation
caused by T-cell dysfunction led to a similar mechanism,
specially given the lymphocytic infiltrate (CD8+ and
CD56+) that was detected in the patient.
The p.Glu297Gly mutation may have altered stability
of γc leading to its reduced level in the patient’s cells
(Fig. 3A). This defect should ultimately lead to suboptimal
signaling by IL-7R pathway and aberrant T-cell develop-
ment, which is in agreement with the naive CD4+ lympho-
penia, as well as the progressive loss of CD3+ cells and
proliferative responses to mitogens, observed in the patient.
However, the residual γc expression on patient’s lym-
phocytes probably allows normal signaling via IL-15R, as
suggested by the normal NK cell count and largely pre-
served STAT5 phosphorylation after stimulation with IL-
15. As shown previously by Smyth and colleagues, in
Epstein-Barr Virus-transformed B-cell lines derived from
X-SCID patients, the amount of γc required for the correct
signaling of various signaling pathways is different. Inter-
estingly, as γc expression becomes limiting, the IL-15R
signal transduction is preferentially preserved relatively to
FIGURE 3. A, Reduced γc expression, shown by control (top) patient
(bottom) gray is isotype control and black is gamma chain. Control
has 96% expression and patient has 15% expression. B, Stat5 tyrosine
phosphorylation analyzed on total lymphocytes (control top panel and
patient bottom panel). Lymphocytes were defined by FSC versus SSC.
Cells were unstimulated (black line) or stimulated with IL-2 (medium
gray), IL-7 (dark gray), or IL-15 (lightest gray). C, Stat5 tyrosine
phosphorylation analyzed on CD4+ lymphocytes (control top panel
and patient bottom panel). Lymphocytes were gated by FSC versus
SSC followed by CD4 versus SSC to define CD4+ lymphocytes. Cells
were unstimulated (black line) or stimulated with IL-2 (medium gray),
IL-7 (dark gray), or IL-15 (light gray). FSC indicates forward scatter;
SSC, side scatter.
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the IL7R, in terms of STAT5 phosphorylation, thus allow-
ing NK cell development but not T-cell development.11,15
Our findings corroborate this mechanism.
In summary, our report adds NRH to the clinical mani-
festations of atypical X-SCID and shows that a novel hypo-
morphic IL2RG p.Glu297Gly (and probably other hypomorphic
mutations) can lead to a progressive loss of T-cell function but
preserved NK cells, resulting in a TlowB+NK+ leaky-SCID.
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